Assistant Professor Position in Solid Tumor Research nature.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nature.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Seattle Cancer Care Alliance Among First Washington Healthcare Providers to Receive COVID-19 Vaccine
December 15, 2020 GMT
Seattle Cancer Care Alliance (SCCA), the only
National Comprehensive Cancer Network (
NCCN )- member cancer center in Washington state, was selected by the Washington State Department of Health to be one of the first 17 sites to receive the recently authorized COVID-19 vaccine. SCCA will receive a portion of the 32,000 doses allotted to Washington State hospitals and will vaccinate its staff, helping to protect the vulnerable patient population that SCCA serves and preserving access to cancer care in the Puget Sound region.
Neal D. Shore, MD, FACS
LHRH agonists are the mainstay for medical castration in advanced prostate cancer, however, they cause an initial testosterone surge with a delayed onset of castration and require depot injection. Although prostate cancer is the most common cancer diagnosis and the second most common cause of cancer death in US men, cardiovascular mortality is the leading cause of death in patients with prostate cancer. Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Read More
Search jobs Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for its clinical pipeline.
The event showcased data from several of Precigen s most advanced clinical programs PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBiotics
TM with presentations and discussions from Precigen executives and key opinion leaders, including Dr. Helen Sabzevari, President and CEO of Precigen, Dr. Pieter Rottiers, CEO of Precigen ActoBio, Dr. Mary L. (Nora) Disis, faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and one of the lead investigators for the PRGN-3005 clinical study, and Dr. Kevan Herold, Professo
Prospect of two coronavirus vaccines spurs hope that pandemic’s end is in sight Carolyn Y. Johnson, Karin Brulliard
How mRNA helped scientists create a covid-19 vaccine in record time
Replay Video UP NEXT A nationwide sense of relief grew Tuesday as a second coronavirus vaccine appeared poised for approval just days after thousands of health-care workers received doses of the first one in an unprecedented mass inoculation campaign that has raised hopes for a return to normalcy. The second vaccine, developed by the biotechnology company Moderna, was “highly effective” in a clinical trial and carried no serious safety concerns, according to a detailed review by the Food and Drug Administration published Tuesday. The agency is likely to authorize the two-shot regimen as soon as Friday, according to a person with knowledge of the situation who was not authorized to discuss the issue.